Feminine hygiene products refer to the products that a woman uses during her menstrual cycle. It is also referred to as menstrual hygiene products. It includes products such as tampons, menstrual cups, sanitary pads, and sea sponges, among others, to manage the symptoms of a woman’s menstrual cycle and to be used during menstruation as panty shields or to protect undergarments from menstrual flow to maintain cleanliness. The main types of feminine hygiene products are sanitary napkins/pads, tampons, panty liners, and menstrual cups. Panty liners are similar to the pad or a sanitary napkin, with lighter and thinner materials, which are generally used to absorb daily vaginal discharge, light menstrual blood flow or post-intercourse discharge, light spotting, staining at the beginning and ends of periods. The products are disposable and reusable and are available in online stores, retail stores, and specialty stores. The feminine hygiene products market research report is one of a series of new reports from The Business Research Company that provides feminine hygiene products market statistics, including feminine hygiene products industry global market size, regional shares, competitors with a feminine hygiene products market share, detailed feminine hygiene products market segments, market trends and opportunities, and any further data you may need to thrive in the feminine hygiene products industry. This feminine hygiene products market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global feminine hygiene products market size grew from $26.87 billion in 2022 to $28.45 billion in 2023 at a compound annual growth rate (CAGR) of 5.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The feminine hygiene products market size is expected to grow to $35.89 billion in 2027 at a CAGR of 6.0%. The growing female population is predicted to positively impact the growth of the feminine hygiene products market. Increased literacy rates, government initiatives to promote gender equality, girls’ education, women empowerment, and maintaining good menstrual health are supporting the female population growth. Feminine hygiene products are used by female during their menstrual cycle to keep themselves clean and hygienic. For instance, according to the Indian government's fifth National Family and Health Survey (NFHS), India has 1,020 women for every 1,000 men between 2019 and 2021. According to demographic estimates provided by the National Commission on Population under the Ministry of Health and Family Welfare, India's population will be more feminine and women would have a better future in the next 15 years. The country's total population sex ratio (females per 1000 males) is predicted to rise by 957 in 2036. Hence, the growing female population drives the growth of feminine hygiene products during the forecast period. Developing eco-friendly feminine hygiene products are shaping the feminine hygiene industry. Ecofriendly feminine hygiene products are made of natural fibers and materials such as wood, bamboo, and hemp that are reusable sustainable alternatives to commercial, mass-produced plastic sanitary pads. For instance, in September 2021, LastObject, a Denmark-based manufacturing company that sells reusable hygiene and skin-care products, announced the launch of its new reusable sanitary towel known as LastPad. It is aimed at reducing waste caused by the disposal of sanitary pads and napkins, which are solely designed for sustainable and reuse purposes. In October 2020, Kimberly-Clark Corporation company, a US-based company that manufactures personal care, paper-based consumer products such as sanitary paper products and surgical and medical instruments Softex Indonesia for an undisclosed amount. This acquisition would engage and accelerates Kimberly-Clark’s growth with a strong market share in the personal care category in Southeast Asia. Softex Indonesia is an Indonesia-based company that is engaged in the manufacturing and marketing of sanitary paper products. Major players in the feminine hygiene products market are Johnson and Johnson, Procter and Gamble, Kimberly-Clark, Essity AB, Kao Corporation, Unicharm Corporation, Ontex, Hengan International Group Company Ltd., Maxim Hygiene, Unilever PLC, Edgewell Personal Care Company, Svenska Cellulosa Aktiebolaget SCA, First Quality Enterprises, Corman, Lil-lets UK Ltd., Natracare, The Honest Company Inc., Seventh Generation Inc., Vivanion, Masmi, Diva International Inc., TZMO S.A, Daio Paper Corporation, Drylock Technologies, Premier FMCG, Bella, Sanofi, Moxie, and Pee Buddy. Asia-Pacific was the largest region in the feminine hygiene products market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the feminine hygiene products market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the feminine hygiene products market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The feminine hygiene products market consists of sales sea sponges, menstrual discs and underwear. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global feminine hygiene products market is segmented - 1) By Type: Sanitary Napkins/Pads, Tampons, Panty Liners, Menstrual Cups 2) By Nature: Disposable, Reusable 3) By Distribution Channel: Online Stores, Retail Outlets, Specialty Stores

Feminine wipes are personal hygiene products made using materials such as cotton, polyester, polypropylene, and cloth. They may contain a soothing agent and offer a daily use solution to women for maintaining menstrual hygiene, eliminating odours, and preventing any infections. Feminine wipes are cleansing cloths used by women to maintain vaginal hygiene during menstruation. The main types of feminine wipes are ordinary and sanitary. Ordinary wipes refer to feminine wipes made using materials such as cotton, wool, polyester, and sometimes a mix of materials that are used suitable to use for everyday purposes. The age group that uses feminine wipes include 5 – 15 years, 16 – 30 years, 31 – 45 years, 46 – 60 years, and 61 and above. The distribution channels of feminine wipes include supermarkets and hypermarkets, convenience stores, pharmacies and drugstores, and online, and other distribution channels. The feminine wipes market research report is one of a series of new reports from The Business Research Company that provides feminine wipes market statistics, including feminine wipes industry global market size, regional shares, competitors with a feminine wipes market share, detailed feminine wipes market segments, market trends and opportunities, and any further data you may need to thrive in the feminine wipes industry. These feminine wipes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global feminine wipes market size grew from $1.88 billion in 2022 to $2.02 billion in 2023 at a compound annual growth rate (CAGR) of 7.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The feminine wipes market size is expected to grow to $2.65 billion in 2027 at a CAGR of 7.1%. Growing education on menstrual hygiene among the female population is expected to propel the growth of the feminine wipes market going forward. Menstrual hygiene is a hygienic approach during menstruation that can prevent women from infection in the reproductive and urinary tract. Education on menstrual hygiene among the female population helps the feminine wipes market by protecting dignity, building confidence, and strengthening sexual and reproductive health. For instance, in May 2022, the World Health Organization, a Switzerland-based specialized agency of the United Nations responsible for international public health, calls on countries to redouble efforts to strengthen menstrual hygiene measures in schools to control adverse health outcomes. Therefore, this increased awareness of menstrual hygiene among the female population is expected to boost demand for feminine wipes during the forecast period. The shift in consumer preferences towards innovative and organic products is an emerging trend gaining popularity in the feminine wipes market. Organic feminine wipes are manufactured using bio-degradable and natural products and do not contain any harsh chemicals. This has led to more women preferring to use organic feminine wipes. For instance, in 2021, according to a survey conducted by Aditi organic certifications Pvt Ltd., an Indian based- government-accredited organic certifications agency, of the 550 consumers participating in the survey from 5 metro cities in India, 62% of consumers reported that they buy organic products frequently. This indicates that more consumers are interested in using organic products.                    In January 2021, Reckitt Benckiser, a UK-based manufacturer of health, nutrition, and hygiene consumer goods acquired, Queen V for an undisclosed amount. Through this acquisition, the company expands Reckitt Benckiser's portfolio of health and wellness brands. Reckitt Benckiser would be able to enter the category of women’s sexual health, hygiene, and wellness through the addition of this brand to its portfolio. Queen V is a US-based vaginal hygiene and wellness company, operating in the feminine wipes market. Major players in the feminine wipes market are Albaad Massuot Yitzhak Ltd., Corman SpA., LA Fresh Group, Guy & O'Neill Inc., Healthy Hoohoo, Intimore Corporation, Johnson & Johnson, Kimberly-Clark Corporation, Laclede Inc., VWash, Unicharm Corporation, Medline Industries Inc., and Boots UK Limited, and SweetSpot Labs. Asia-Pacific was the largest region in the feminine wipes market in 2022. The regions covered in the feminine wipes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the feminine wipes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The feminine wipes market consists of sales of wet wipes pH balanced, vitamin-e & aloe wipes, and toilet wipes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global feminine wipes market is segmented - 1) By Type: Ordinary, Sanitary 2) By Age group: 5–15 years, 16–30 years, 31–45 years, 46–60 years, 61 and above 3) By Distribution Channel Outlook: Supermarkets and Hypermarkets, Convenience Stores, Pharmacies and Drugstores, Online, Other Distribution Channels

Polycystic ovarian syndrome is a disorder in which hormones are out of control for females and they have male hormones that are higher than normal, which causes them to skip menstrual periods and makes pregnancy more difficult for them. The main drug types in the polycystic ovarian syndrome treatment market are oral contraceptives, ornithine decarboxylase inhibitors, insulin-sensitizing agents, anti-depressants, diuretics, and aromatase inhibitors. Oral contraceptives are hormone-based drugs that are taken orally to prevent pregnancy. They prevent pregnancy by slowing ovulation and preventing sperm from entering the cervix. The various surgery types include ovarian wedge resection and laparoscopic ovarian drilling, which are performed in hospitals and clinics, ambulatory surgical centers, diagnostic centers, gynecology centers, and feminist health centers. The polycystic ovarian syndrome treatment market research report is one of a series of new reports from The Business Research Company that provides polycystic ovarian syndrome treatment market statistics, including polycystic ovarian syndrome treatment industry global market size, regional shares, competitors with a polycystic ovarian syndrome treatment market share, detailed polycystic ovarian syndrome treatment market segments, market trends and opportunities, and any further data you may need to thrive in the polycystic ovarian syndrome treatment industry. This polycystic ovarian syndrome treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global polycystic ovarian syndrome treatment market will grow from $4.26 billion in 2022 to $4.49 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global polycystic ovarian syndrome treatment market is expected to grow to $5.66 billion in 2027 at a CAGR of 5.9%. The global rise in genetic and hormonal disorders is a key factor driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. PCOS is a prevalent hormonal disorder among premenopausal women worldwide, with reproductive, endocrine, and metabolic abnormalities. The PCOS prevalence ranges from 2.2% to 26% globally and is highly variable. In China, the figures range between 2% to 7.5% and 6.3% in Sri Lanka, 9.13% in south India and 22.5% in Maharashtra. The rise in genetic and hormonal disorders globally is expected to increase the growth of the polycystic ovarian syndrome treatment market. Lack of drugs approved by regulatory bodies such as FDA (Food and Drug Administration) among many countries is a key factor hampering the growth of the polycystic ovarian syndrome treatment market. FDA has not approved pharmacological treatment for use in adolescents with PCOS. However, some pharmacological interventions are used to treat PCOS symptoms. For instance, rimonabant, a key appetite suppressant cannabinoid CB1 receptor antagonist was not approved by the United States Food and Drug Administration (FDA) in the USA due to concerns about suicidal ideation and drug overdoses. Moreover, Minoxidil is the only drug approved by FDA, used for the treatment of female pattern baldness. Therefore, the lack of regulatory body approved drugs in many countries is a key factor restraining the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a major trend driving the growth of the polycystic ovarian syndrome treatment market. Laparoscopic ovarian drilling is a surgical treatment performed by doctors in critical conditions that can cause ovulation in women with polycystic ovary syndrome (PCOS). Ovarian drilling is often used by women with PCOS who often do not ovulate despite having attempted weight loss and the use of fertility drugs. According to a 2021 study published on Taylor and Francis online, an American open access journal, the efficacy of ovarian drilling was variable in different literature. Ovulation and pregnancy rates were found to be 30%-90% and 13%-80% respectively. In December 2021, Organon& Co., an American pharmaceutical company working to improve women’s health, acquired Forendo Pharma for $954 million. Through this acquisition Organon plans to bring innovation in the area of women’s health and develop better treatments. Forendo Pharma is a Finland-based clinical stage pharmaceutical company pioneering in the areas of intracrinology and polycystic ovarian syndrome (PCOS). Major players in the polycystic ovarian syndrome treatment market are Bristol-Myer Squibb Company, Bayer AG, Pfizer Inc., Merck KGaA, Sanofi, AstraZeneca, Novartis AG, Teva Pharmaceutical Industries Limited, Abbott, Addex Therapeutics Ltd., BIOCAD, Allergan PLC., Johnson and Johnson, Ferring BV, and Ferring Pharmaceuticals Inc. North America was the largest region in the polycystic ovarian syndrome treatment market in 2022. Western Europe was the second largest region in the global polycystic ovarian syndrome treatment market. The regions covered in the global polycystic ovarian syndrome treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the polycystic ovarian syndrome treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The polycystic ovarian syndrome treatment market includes revenue earned by first line drugs for treating hirustism, first line drugs for ovulation, and insulin sensitizing drugs. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global polycystic ovarian syndrome treatment market is segmented - 1) By Drug Type: Oral Contraceptives, Ornithine Decarboxylase Inhibitors, Insulin-Sensitizing Agents, Anti-Depressants, Diuretics, Aromatase Inhibitors 2) By Surgery Type: Ovarian Wedge Resection, Laparoscopic Ovarian Drilling 3) By End User: Hospitals & Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Gynecology Centers, Feminist Health Centers

Hormonal contraceptive refers to a method of birth control that stops pregnancy using hormones. There are numerous types. Some can be undone, while others are irreversible. Some varieties can also aid in the prevention of STDs. The main types of products in oral contraceptive pills are injectable birth control, emergency contraceptive pills, vaginal rings, and others. Any class of synthetic steroid hormones which inhibit the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from the anterior lobe of the pituitary gland in the female body is known as oral contraceptive pills or birth control pills. The different hormones include progestin-only, and combined hormones and are used by hospitals, homecare settings, gynecologycenters, clinics, and ambulatory surgical centers. It is distributed through various channels such as drug stores, gynecology or fertility clinics, e-commerce, and others. The hormonal contraceptives market research report is one of a series of new reports from The Business Research Company that provides hormonal contraceptives market statistics, including hormonal contraceptives industry global market size, regional shares, competitors with a hormonal contraceptives market share, detailed hormonal contraceptives market segments, market trends and opportunities, and any further data you may need to thrive in the hormonal contraceptives industry. This hormonal contraceptive market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global hormonal contraceptives market size will grow from $13.47 billion in 2022 to $13.78 billion in 2023 at a compound annual growth rate (CAGR) of 2.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global hormonal contraceptives market size is expected to grow to $14.56 billion in 2027 at a CAGR of 1.4%. Increased awareness about the benefits and use of contraceptives is a major factor driving the hormonal contraceptives market. According to the World Health Organization (WHO), 16 million girls worldwide aged 15-19 give birth every year which accounts for approximately 11% of all births globally. To prevent these unplanned births global awareness programs such as It’s your life, it’s your future by the WHO and world contraception day was initiated. The London Summit on Family Planning urged governments, international agencies, and another private sectors to commit to improving access to voluntary family planning. This gave rise to the global partnership, Family Planning 2020 (FP2020). FP2020 has created momentum worldwide on issues such as access to contraceptives, more innovation, and greater accountability in family planning efforts. For example, India will have spent USD$3 billion by 2020 to spread awareness and improve family planning in the country. Moreover, in 2020, according to the United Nations Department of Economic and Social Affairs, about 1.1 billion women aged between 15 and 49 are considered to need family planning. The market for hormonal contraceptive drugs is restrained by the growing use of biologics in place of traditional chemical drugs. Biologics are medicines containing one or more substances derived from a biological source like micro-organisms, animal cells, or human cells. The ability to interact with specific targets puts these medicines above any other drugs, thus hampering the market of chemical-hormonal contraceptive drugs. Companies are innovating to manufacture chewable low-dose oral contraceptives that reduce side effects. The chewable contraceptive initiative was an attempt to reduce side effects while at the same time making it easier for the patients to get into a daily regimen of using this contraceptive. The pill is already being sold as an over-the-counter product. Some of the top companies that produce and sell chewable low-dose oral contraceptives, for instance, are Lupin pharmaceuticals, Walter Chilcott, and Watson pharmaceuticals. Manufacturers in the hormonal contraceptives market should abide by many strict regulations about labeling hormonal contraceptives, and are all supervised by regulatory authorities. For instance, the US FDA has drafted a new set of guidance and labeling recommendations in the hormonal contraceptives market. The main purpose of PLR is to enhance the safety and usage of the particular prescribed drug by providing healthcare providers with clear prescription information (PI). The FDA mandates all hormonal contraceptives to mention the effectiveness of the drug in preventing STDs and any other relevant information regarding the effectiveness of the drug. The FDA considers that communicating information regarding pregnancy rates to the users of these contraceptive drugs is essential for safety and effective usage. Major players in the hormonal contraceptives market are Bayer AG, Merck & Co. Inc., Pfizer, Allergan, Afaxys Inc., TevaPharma Industries Ltd., Agile Therapeutics, HLL Lifecare Limited, Lupin Pharmaceuticals Inc. and Piramal Healthcare Limited. North America was the largest region in the hormonal contraceptives market in 2022. Middle East is expected to be the fastest-growing region in the global hormonal contraceptives market during the forecast period. The regions covered in the global hormonal contraceptives market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the hormonal contraceptives market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The hormonal contraceptive market includes revenues earned by entities by blocking the release of eggs from the ovaries and thinning the lining of the uterus to prevent pregnancy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global hormonal contraceptives market is segmented - 1) By Product: Oral Contraceptive Pills, Injectable Birth Control, Emergency Contraceptive Pills, Vaginal Rings, Other Products 2) By End Users: Hospitals, Homecare Settings, Gynaecology Centers, Clinics, Ambulatory surgical centers 3) By Hormones: Progestin-Only, Combined Hormones 4) By Distribution Channel: Drug Stores, Gynaecology/ Fertility Clinics, E-Commerce, Other Distribution Channels

Gynecology drugs refer to a field of medicine that focuses on the treatment of illnesses of the female reproductive system, including care for women during pregnancy and childbirth. These drugs are used to treat gynecological diseases which include conditions and affecting the uterus, ovaries, and their appendages. The main types of therapeutics in gynecology drugs are hormonal therapy and non-hormonal therapy. Hormonal therapy is a treatment that adds, blocks or removes hormones to slow or stop the growth of cancer cells that need hormones to grow. Non-hormonal therapy involves the usage of anti-infective, anti-inflammatory agents, lubricants, moistures, antidepressants, gabapentin, clonidine and others. Gynecology drugs are used for gynecology cancers, menopausal disorder, polycystic ovary syndrome, contraception and others and distributed through hospital pharmacies, retail pharmacies and online pharmacies. The gynecology drugs market research report is one of a series of new reports from The Business Research Company that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gynecology drugs market size grew from $26.46 billion in 2022 to $28.09 billion in 2023 at a compound annual growth rate (CAGR) of 6.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gynecology drugs market size is expected to grow to $36.23 billion in 2027 at a CAGR of 6.6%. The rise in the number of women suffering from ovarian cancer would drive the growth of the global gynecological drugs market. For instance, according to Globocan, it is estimated that the global incidence of ovarian cancer will increase from 295,414 in 2018 to 434,184 by 2040. The increasing incidence of ovarian cancer would boost the market for gynecological drugs in the forecast period. Alternative treatment methods and natural remedies are increasingly becoming popular globally which is expected to have a negative impact on the revenues of gynecological drug companies. Treatments in the fields of homoeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, Ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for gynecological cancer. Many herbs used in Ayurveda have anti-cancer properties, for example, Curcumin, Holy Basil is said to inhibit the growth of cancerous cells and Ayurvedic gynecological procedures like Agnikarma help treat cervical erosion. This growing adoption of alternative treatments is expected to have a negative impact on the growth of the market. Drug manufacturers are investing in developing personalized cancer vaccines, including gynecological cancers, and few have reached clinical trial phases. Pharmaceutical companies are combining genetic sequencing and precision medicine to create new drug therapies and cancer treatments that are designed to treat specific patients. Moderna announced the result of the ongoing Phase 1 clinical study in patients with both resected (adjuvant) and unresected (advanced) solid tumours. The results were positive when mRNA mRNA personalized cancer vaccine (PCV) mRNA-4157, was given alone or in combination with Merck pembrolizumab (KEYTRUDA®). Currently, the vaccine is in phase 2 clinical trial. In January 2020, India-based capital market company True North announced the acquisition of India-based Glenmark Pharmaceuticals Ltd gynecology business in India and Nepal for $16.2 million (INR 115 crore). Through this acquisition, True North aims to further grow the gynecology portfolio of Glenmark and expanding presence in multiple geographies. Major players in the gynecology drugs market are Hoffmann-La Roche Ltd., Pfizer Inc., Merck & Co. Inc., Allergan, AstraZeneca, Bayer AG, AbbVie, TherapeuticsMD Inc., Lupin Pharmaceuticals Inc., Ferring Holding SA, Johnson & Johnson, GlaxoSmithKline PLC., Eli Lilly and Company, Amgen Inc., and Sanofi. North America was the largest region in the gynecology drugs market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global gynecology drugs market is segmented - 1) By Therapeutics: Hormonal Therapy, Non-Hormonal Therapy 2) By Indication: Gynecology Cancers, Menopausal Disorder, Polycystic Ovary Syndrome, Contraception, Other Indications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Gynaecology medical lasers are used in the treatment of gynaecological conditions. The gynaecology medical lasers market covered in this report is segmented by product type into CO2 laser, KTP–argon laser, and Nd:YAG laser. The CO2 laser aids in the removal of thin layers of skin while causing minimal damage to the surrounding structures.The various applications involved are colposcopy, laparoscopy, and hysteroscopy, which are used by end-users such as hospitals, specialised clinics, ambulatory surgical centres, and medical centres. The gynaecology medical lasers market research report is one of a series of new reports from The Business Research Company that provides gynaecology medical lasers market statistics, including gynecology medical lasers industry global market size, regional shares, competitors with a gynaecology medical lasers market share, detailed gynaecology medical lasers market segments, market trends and opportunities, and any further data you may need to thrive in the gynaecology medical lasers industry. This gynaecology medical lasers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global gynecology medical lasers market grew from $0.22 billion in 2022 to $0.31 billion in 2023 at a compound annual growth rate (CAGR) of 44.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The gynecology medical lasers market is expected to grow from $1.26 billion in 2027 at a CAGR of 41.3%. Rising obesity is expected to drive the gynecology medical lasers market. Overweight women have a higher incidence of gynecology disorders. Overweight and obese women are at high risk of reproductive health-related issues. They have a higher risk of infertility, conception rates, miscarriage rates, and increased risk for pregnancy complications. They have poor reproductive outcomes in natural as well as assisted conception. Increasing obesity in women across the globe is driving the demand for gynecology treatment, hence driving the gynecology medical lasers market. The high costs associated with gynecology lasers are a major issue faced by patients across the globe, especially in developing countries. The pressure to contain costs and demonstrate value is widespread. Political uncertainty and persistent economic stress in numerous countries are calling into question the sustainability of public health care funding. Carbon dioxide laser is the system most commonly used in gynecology and the main indications are a disease of the uterine cervix, vagina, vulva, or perineum. The only disadvantage is their high cost. For instance, CO2 laser therapy costs more than $500 per treatment, with three treatments required initially, followed by annual treatments. Therefore, the high cost of gynecology laser treatment and the lack of skilled technicians in developing countries hamper the demand for such lasers and impact market growth. Gynecology medical laser manufacturers are constantly investing in technologies for faster diagnosis and efficient treatment of gynecological conditions. Areas of technological advances include new wavelengths, more rugged setups, lower-cost systems, and other advancements are being combined with minimally invasive techniques. For instance, FDA cleared the use of the Dynamis PRO laser system for treatments in gynecology and genitourology, which uses two complementary wavelengths, for fast and precise treatments. Major players in the gynaecology medical lasers market are Quanta System S.p.A, Cynosure, Biolitec AG, Boston Scientific Corporation, DEKA Medical, Limmer Laser, Linline Medical Systems, Fotona, GIGAA Laser, and LISA laser products. North America was the largest region in the gynecology medical lasers market in 2022. Asia-Pacific was the second largest region in the global gynaecology medical lasers market report. The regions covered in the global gynaecology medical lasers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the gynaecology medical lasers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The gynecology medical lasers market consists of sales of instruments that include Nd:YAG, neodymium, and potassium-titanyl-phosphate (KTP). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global gynaecology medical lasers market is segmented - 1) By Product Type: CO2 Laser, KTP–Argon Laser, Nd:YAG Laser 2) By Application: Colposcopy, Laparoscopy, and Hysteroscopy 3) By End-User: Hospital, Specialized Clinics, Ambulatory Surgical Centers, Medical Centers

Fertility treatment is a medical treatment provided to a man or a woman to increase their chances of bearing an offspring. It is used to treat infertile patients. Hormone and ovulation-supporting medicines are frequently used in fertility treatments, sometimes in conjunction with minor surgical procedures. The main product types of fertility are reagents, and equipment. A reagent is a material or compound that is added to a system to produce a chemical reaction or to determine whether or not a reaction occurred. The treatments are performed on female and male in fertility clinics, hospitals, surgical centers, and clinical research institutes. The fertility treatment market research report is one of a series of new reports from The Business Research Company that provides fertility treatment market statistics, including fertility treatment industry global market size, regional shares, competitors with a fertility treatment market share, detailed fertility treatment market segments, market trends and opportunities, and any further data you may need to thrive in the fertility treatment industry. This fertility treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fertility treatments market grew from $15.26 billion in 2022 to $16.48 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fertility treatments market is expected to grow from $22.77 billion in 2027 at a CAGR of 8.4%. The growth in the median age of first-time motherhood combined with change in lifestyle increased the difficulty of conceiving, increasing the demand for fertility treatment. The median age of first-time motherhood has increased all over the globe due to late marriages, contraceptive techniques, and an increase in the number of women who prioritize their careers over starting a family. In 2020, the average age of first-time mothers in America has risen from 21 to 26. Women in other developed countries are also deferring, with the typical first birth occurring at the age of 31 for new mothers. In this scenario, a growing number of women are opting for IVF treatments, which is expected to drive this market. The high cost and low success rate of In vitro fertilization (IVF) treatment is a major factor that limits the growth of the fertility treatments market. In vitro fertilization is a fertilization process in which an egg is fertilized with sperm outside the body, in vitro. In vitro fertilization (IVF) treatment costs differ in many countries due to the lack of refund policies. Moreover, insurance companies usually do not cover infertility treatments. According to the American society of reproductive medicine, in the USA, the average cost of an IVF cycle is $12,400 and the average cost of an IVF cycle using fresh embryos is $8,158 with a median cost at $7,500. The rate of success of IVF treatments is only 28% to 35%, which decreases with the increase in woman's age. For example, for women, the success rate is 32.2% under 35 and 1.9% for women aged over 44. Thus, the high cost and low success rate of IVF treatment restrict the growth of the fertility treatment market. Development of new techniques to treat infertility using a human’s body is a key trend in the fertility treatments market. INVOcell is an IVF alternative that uses the woman’s body to support fertilization, thus eliminating the cost of a laboratory incubator. The INVOcell device is placed with the eggs and sperm in the vaginal cavity, allowing for the stability of the natural environment, pH, and gas to help in fertilization. INVOcell, which is made in Medford, Massachusetts by INVO Bioscience, costs around $6,800 including medication. Although IVF generated more quality embryos, the birth rates between IVF and INVOcell are similar. According to the journal of assisted reproduction and genetics, 12 out of 20 women gave birth to 15 babies in IVF including three sets of twins and 11 out of 20 women gave birth to 16 babies in INVOcell group including five sets of twins. In August 2022, CCRM Fertlity, an American fertility treatment company, acquired Institute for Reproductive Medicine & Sciences (IRMS) for an undisclosed amount. The acquisition would add world class proprietary reproductive medicine offerings to the CCRM’s portfolio and expand its footprint across 11 major metropolitan areas with 34 locations across the US and Canada. Institute for Reproductive Medicine and Science (IRMS) is a US-based fertility research and treatment company having its presence in major metropolitan areas. Major players in the fertility treatment market are Apollo Hospitals Enterprise Ltd., Care Fertility Group, Genea Limited, The Johns Hopkins Health System Corp., Medicover Group, Monash IVF Group, Progyny Inc., Vitrolife, Carolinas Fertility Institute, OvaScience Inc., Xytex Cryo International, Merck KGaA, Cook Medical, CooperSurgical Inc., Instituto Bernabeu, INVO Bioscience, The Cooper Companies Inc., Virtus Health, CryoChoice LLC., Millendo Therapeutics Inc., FUJIFILM Irvine Scientific, LABOTECT GMBH, Fertility Focus, Olympus Corporation, Irvine Scientific sales Company Inc., and Ferring Pharmaceuticals. North America was the largest region in the fertility treatment market in 2022. Western Europe was the second largest region in the global fertility treatment market. The regions covered in the global fertility treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fertility treatment market includes revenues earned by entities by providing medicinal services, surgical services, and assisted services such as in vitro fertilization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility treatments market is segmented - 1) By Product: Reagents, Equipment 2) By End-User: Fertility Clinics, Hospitals, Surgical Centers, Clinical Research Institutes 3) By Patient Type: Female, Male

Fertility drugs refer to a term used to describe medications that cause your body to release hormones that regulate or prompt ovulation, or the release of an egg from your ovary. The main types of fertility drugs are prescription fertility drugs and over-the-counter fertility drugs. The drugs are administered orally, intravenously, subcutaneously, and intramuscularly to male and female patients. Subcutaneous administration refers to the process of injecting the drugs into the fatty tissue just beneath the skin. The drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacies. The fertility drugs market research report is one of a series of new reports from The Business Research Company that provides fertility drugs market statistics, including fertility drugs industry global market size, regional shares, competitors with a fertility drugs market share, detailed fertility drugs market segments, market trends and opportunities, and any further data you may need to thrive in the fertility drugs industry. This fertility drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global drugs for infertility market size will grow from $2.93 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 3.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global drugs for infertility market size is expected to grow to $3.30 billion in 2027 at a CAGR of 2.1%. The growth of the market for fertility drugs is driven by the increasing rates of infertility across the globe. Infertility is the inability to conceive after trying for 12 consecutive months. Fertility drugs are widely used to treat infertility in both men and women. The rising rates of infertility are attributed to physiological problems, hormone problems, and lifestyle or environmental factors. To treat infertility problems in women, fertility drugs are used to regulate their ovulation cycles, which affects the sale of these drugs. For instance, in September 2020, according to the World Health Organization (WHO), a Switzerland-based international public health organization, millions of people in the world who are of reproductive age will struggle with infertility, which will also have an effect on their families and communities. Worldwide, it is estimated that 48 million couples and 186 million people struggle with infertility. Hence, the rising cases of infertility across the globe are increasing the demand for fertility drugs, resulting in the growth of the fertility drug market. The side effects caused due to fertility drugs restricted the growth of the fertility drugs market. Fertility drugs can result in permanent as well as temporary side effects. Temporary side effects include bloating, headache, breast tenderness, upset stomach, hot flashes, and mood swings whereas the permanent side effects include multiple pregnancies, and ovarian hyperstimulation syndrome (OHSS). OHSS is a condition where the ovaries enlarge with fluids and may become life-threatening if left untreated. For instance, the intake of Clomid (clomiphene citrate), a fertility drug for women, can result in OHSS along with abnormal vaginal/uterine bleeding, breast tenderness or discomfort, headache, nausea, vomiting, diarrhea, flushing, blurred vision, or other visual disturbances. The fear of potential side effects of fertility drugs restricts the growth of the fertility drugs market. The companies in the fertility drugs market are focusing on the launch of self- administration fertility solutions for advanced infertility treatment. The self- administration fertility solution makes it easier and less painful for women to self-administer daily injections. For example, in August 2021, Merck Specialities, the healthcare business of Merck in India, launched Pergoveris Pen for advanced infertility treatment in India. This launch aims to fulfill unmet medical needs by providing an improved, convenient, and ready-to-use combination treatment option for women with a severe follicle-stimulating hormone (FSH) and luteinizing hormone (LH) deficiency. The Pergoveris Pen is a combination of a freeze-dried powder and solvent, reducing the probability of reconstitution errors. As a result, Pergoveris delivers with more precision and, hence, is more accessible to self-administration by patients during infertility treatment. In January 2020, Evotec SE, a Germany-based pharmaceutical company specialising in drug discovery and development, announced strategic partnerships with Bayer AG, a pharmaceutical and biotechnology company pioneering in the discovery, development, manufacturing, and commercialization of drugs. Under this collaboration, to develop a new cure and multiple clinical candidates for the treatment of polycystic ovary syndrome together, both businesses will offer drug targets and a wide array of high-quality technological platforms. Major players in the fertility drugs market are Merck & Co., Ferring Pharmaceuticals, Bayer, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer, Novartis AG, Procter & Gamble Pharmaceutical, Zydus Pharma, LIVZON, Abbott, MSD, Sanofi S.A., Eli Lilly and Co., Serono, Inc., Novogyne Pharmaceuticals, and Takeda Pharmaceutical co. ltd. North America was the largest region in the fertility drugs market in 2022. The Middle East is expected to be the fastest-growing region in the global drugs for infertility market during the forecast period. The regions covered in the global fertility drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the fertility drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The fertility drugs market consists of sales of clomiphene citrate, gonadotropins, and metformin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fertility drugs market is segmented - 1) By Gender: Male, Female 2) By Route of Administration: Oral, Intravenous, Subcutaneous, Intramuscular 3) By Type Of Drug: Prescription Fertility Drugs, Over-The-Counter Fertility drugs 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies